IHH: Valuation Concerns Lead to Neutral Rating for Healthcare Giant Despite Upgraded Forecasts

A leading investment bank has adjusted its recommendation for a prominent healthcare provider from “Buy” to “Neutral”, citing valuation concerns despite a positive revision of future earnings forecasts. The target price has been marginally lowered to MYR9.41, indicating a 5.1% upside from its previous level of MYR9.52. This adjustment reflects a view that the current share price offers limited room for appreciation, leading to a balanced risk-reward profile.

Earnings Outlook and Performance Drivers

The bank raised its earnings forecasts for the healthcare group for fiscal years 2026, 2027, and 2028 by 1%, 3%, and 5% respectively, following an update of key earnings assumptions. EBITDA margin forecasts are expected to remain within management’s guided range of 22-24%. For 2026, the company is projected to achieve low-to-mid teens constant currency growth in both revenue and EBITDA, building on an 18%/14% growth recorded in 2025.

Malaysia stands out as a strong performer, having posted a 29% EBITDA margin in 4Q25. However, this is anticipated to normalize towards the mid-20% range due to factors such as wage increases and supplier renegotiations. In India, weaker EBITDA margins were attributed to one-off expenses related to labour code and property revaluation, with underlying margins expected to be closer to 20%.

Operational Landscape and Future Strategy

Operational challenges are noted in Singapore, where the stabilisation of Mount Elizabeth Orchard has been pushed back to the second half of 2026, primarily due to a weaker-than-expected rebound. Furthermore, the newly opened 200-bed transitional care facility has impacted Singapore’s EBITDA margin. The introduction of targeted treatment packages aims to enhance competitiveness but might moderate inpatient revenue intensity. Conversely, growth momentum in Turkey and Europe is expected to remain robust.

The group’s 2030 Strategy remains a cornerstone of its future plans, focusing on capital efficiency improvements through a pivot towards the day care model, which helps free up inpatient bed capacity. The target to add over 4,000 beds is maintained, though the timeline has been extended to 2030. Expansion efforts will concentrate on brownfield developments in regions experiencing structural bed shortages, notably India and Malaysia. These expansions are slated for internal funding and are anticipated to be ROE-accretive.

Risks and Investment Conclusion

Key downside risks identified include softer-than-expected economic growth impacting patient volumes, aggressive cost inflation across operational markets that hinder the ability to pass through increased costs, and foreign exchange volatility leading to translation losses. Conversely, more robust economic conditions, successful cost management, and favorable currency movements present potential upside risks. The bank concludes that, given the current valuation, the risk-reward profile is balanced, justifying the “Neutral” rating.